Our activity for the development of ensitrelvir (Xocova) was introduced in the Hokkaido University’s official website.
Please check our recent work published from Science Translational Medicine!
Sasaki M, et al., S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters. Sci Transl Med. 2022 Nov 3
https://www.science.org/doi/10.1126/scitranslmed.abq4064
New COVID-19 drug developed by Shionogi & Co., Ltd. and Hokkaido University approved in Japan